Breaking News Instant updates and real-time market news.

GNW

Genworth

$3.82

0.11 (2.97%)

, KKR

KKR

$22.99

0.49 (2.18%)

19:28
06/10/18
06/10
19:28
06/10/18
19:28

On The Fly: Top five weekend stock stories

Catch up on the weekend's top five stories with this list compiled by The Fly: 1. China Oceanwide and Genworth Financial (GNW) announced that the Committee on Foreign Investment in the United States, or CFIUS, has completed its review of their proposed transaction and concluded that there are no unresolved national security concerns with respect to the proposed transaction. This satisfies one of the conditions to the closing of the proposed transaction. The closing of the transaction remains subject to other conditions, including the receipt of required regulatory approvals in the U.S., China and other international jurisdictions. 2. KKR (KKR) is nearing an agreement to acquire U.S. physician services provider Envision Healthcare (EVHC) for $46 a share, or about $5.5B, according to Reuters, citing a person familiar with the matter. 3. Fast growth in grid storage will make wind power even more competitive, which is good news for utilities with plenty room to add wind capacity like American Electric (AEP) and Xcel (XEL) and for wind developers like NextEra (NEE), Jack Hough wrote in this week's edition of Barron's. Nuclear-heavy companies in deregulated markets like Exelon (EXC) and Public Service Enterprise Group (PEG), on the other hand, could face rising competitive pressures, he added. 4. The female-fronted "Ocean's 8" opened over the weekend to a $41.5M from 4,145 theaters to place number 1 in North America. Overseas, the Warner Bros. (TWX) and Village Roadshow pic grossed $12.2M for a global start of $53.7M. "Ocean's 8" earned a B+ CinemaScore and sports a 68% Rotten Tomatoes score. 5. AbbVie (ABBV), Pfizer (PFE), Merck (MRK), Bristol-Myers Squibb (BMY), Johnson & Johnson (JNJ), Eli Lilly (LLY), Southwest (LUV), BMW (BMWYY), Volkswagen (VLKAY), Altaba (AABA) saw positive mentions in Barron's.

GNW

Genworth

$3.82

0.11 (2.97%)

KKR

KKR

$22.99

0.49 (2.18%)

EVHC

Envision Healthcare

$43.63

0.66 (1.54%)

AEP

American Electric

$64.12

-0.03 (-0.05%)

XEL

Xcel Energy

$42.69

-0.03 (-0.07%)

NEE

NextEra Energy

$156.78

0.46 (0.29%)

EXC

Exelon

$40.00

-0.14 (-0.35%)

TWX

Acquired by T

$95.36

-0.03 (-0.03%)

ABBV

AbbVie

$100.41

1.115 (1.12%)

PFE

Pfizer

$36.67

0.18 (0.49%)

MRK

Merck

$62.57

0.6 (0.97%)

BMY

Bristol-Myers

$53.16

0.56 (1.06%)

JNJ

Johnson & Johnson

$124.04

0.76 (0.62%)

LLY

Eli Lilly

$86.13

0.27 (0.31%)

LUV

Southwest

$50.48

-0.16 (-0.32%)

BMWYY

BMW

$0.00

(0.00%)

VLKAY

Symbol is now VWAGY

$0.00

(0.00%)

AABA

Altaba

$80.58

0.88 (1.10%)

  • 11

    Jun

  • 12

    Jun

  • 18

    Jun

  • 26

    Jun

  • 28

    Jun

  • 10

    Jul

  • 26

    Jul

  • 10

    Sep

  • 23

    Oct

GNW Genworth
$3.82

0.11 (2.97%)

09/15/17
BTIG
09/15/17
NO CHANGE
BTIG
Genworth still faces long road, says BTIG
BTIG analyst Mark Palmer says that Virginia's decision to approve the sale of Genworth's insurance companies in the state to a Chinese company, China Oceanwide, is positive. However, the analyst says that Genworth still must obtain the approval of "several (other) entities" before its deal to sell the entire company to China Oceanwide can close. He believes that Genworth's stock could fall below $1 if the deal is not approved as such a development would "spark fears of an imminent bankruptcy filing," according to the analyst. He keeps a Neutral rating on the shares.
KKR KKR
$22.99

0.49 (2.18%)

05/16/18
SBSH
05/16/18
UPGRADE
Target $27
SBSH
Buy
KKR upgraded to Buy from Neutral at Citi
Citi analyst William Katz upgraded KKR to Buy and raised his price target for the shares to $27 from $23.50. The analyst believes the company's C-Corp conversion will increase relevance of the sector and raise the absolute upside for KKR. His higher price target incorporates increased balance sheet value, lower cost of capital to discount performance fees, and tax benefits related to the C Corp conversion.
06/05/18
RHCO
06/05/18
NO CHANGE
Target $90
RHCO
Buy
Amedisys's robust free cash flow 'a good thing,' says SunTrust
SunTrust analyst David MacDonald said he is "bullish" on Amedisys (AMED) following the repurchase of 2.4M shares from KKR (KKR), telling investors in a research note that the company's pristine balance sheet, strong free cash flow and expected near-term upsizing of the credit facility should give Amedisys plenty of dry power to ramp M&A activity. MacDonald raised his price target to $90 from $85 and maintained a Buy rating on the stock.
05/16/18
05/16/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Urban Outfitters (URBN) upgraded to Neutral from Sell at MKM Partners with analyst Roxanne Meyer citing her expectations of a sales and margin recovery in the second half, with fourth quarter commentary suggesting improving trends after the company's worse than expected performance in 2017. 2. AMD (AMD) upgraded to Neutral from Negative at Susquehanna with analyst Christopher Rolland saying Ethereum prices have doubled in the last month, driving a "modest" reacceleration in GPU purchases, while price hikes have "destroyed value proposition" of a rival Ethereum ASIC. 3. TripAdvisor (TRIP) upgraded two notches to Outperform from Underperform at Macquarie with analyst Matthew Brooks saying TripAdvisor raised their EBITDA forecast to up from flat, and now believes it could grow above 20% in 2018, with a margin rise for the first time since 2011. 4. KKR (KKR) upgraded to Buy from Neutral at Citi with analyst William Katz saying he believes the company's C-Corp conversion will increase relevance of the sector and raise the absolute upside for KKR. 5. Chipotle (CMG) upgraded to Buy from Hold at Argus with analyst John Staszak saying the current valuation does not adequately "reflect prospects for accelerating same-store sales and earnings growth as the company continues its multiyear recovery." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/05/18
SPHN
06/05/18
NO CHANGE
Target $78
SPHN
Equal Weight
Amedisys buying back shares from KKR a 'win-win,' says Stephens
Stephens analyst Dana Hambly called Amedisys' (AMED) repurchase of about 2.4M of its common shares from KKR (KKR) a "creative way to deploy excess capital" and create shareholder value while also returning capital to KKR and not impacting Amedisys' ability to pursue M&A. He also noted that the company is in advanced talks to increase borrowing to support M&A. Hambly raised his 2019 EPS estimate by 6% to account for the buybacks and raised his price target on Amedisys to $78 from $73, though he keeps an Equal Weight rating on the stock, citing valuation.
EVHC Envision Healthcare
$43.63

0.66 (1.54%)

04/11/18
BARD
04/11/18
NO CHANGE
Target $50
BARD
Outperform
Envision Healthcare added as a Fresh Pick at Baird
Baird analyst Whit Mayo noted Envision Healthcare (EVHC) shares are down more than $7 since it was leaked UnitedHealth (UNH) was potentially terminating its contract with them, but he believes it could be a bargaining tactic by UnitedHealth to position itself to reprice its contract. With Envision's valuation decline, the shares were added as a Fresh Pick as he believes the company is setting up for a compelling risk/reward. Mayo reiterated his Outperform rating and $50 price target on Envision Healthcare shares.
04/11/18
JEFF
04/11/18
NO CHANGE
Target $46
JEFF
Buy
Envision selloff yesterday an 'unwarranted overreaction,' says Jefferies
Yesterday's selloff in shares of Envision Healthcare (EVHC) is an "unwarranted overreaction" to "misleading headlines" regarding news that has been known for three weeks, Jefferies analyst Brian Tanquilut tells investors in a research note. The analyst sees the worst case scenario as UnitedHealth (UNH) to terminating its Envision Healthcare contract at year-end. However, it is important to note that Envision is unlikely to lose its UnitedHealth business even in that scenario as the company will merely move "out-of-network" with the payor, Tanquilut writes. Further, the analyst continues to expect Envision's strategic review to result in a sale. He keeps a Buy rating on the shares with a $46 price target.
04/26/18
04/26/18
NO CHANGE

Strong Buy
Envision Healthcare weakness a buying opportunity, says Raymond James
Raymond James analyst John Ransom recommends buying Envision Healthcare (EVHC) on weakness today related to noted short-seller Jim Chanos comments on CNBC that he thinks Mednax (MD) and Envision Healthcare "may be worth nothing." Ransom believes the thesis is "inaccurate" and believes Envision could be sold at 15x proforma 2019 EBITDA, which would equate to the low $50's, based on a similar sale price of the physician practice sold by Fresenius Medical (FMS). The analyst rates Envision Healthcare a Strong Buy with a $55 price target.
04/10/18
CANT
04/10/18
NO CHANGE
Target $40
CANT
Neutral
UnitedHealth news 'particularly damaging' to Envision, says Cantor Fitzgerald
Cantor Fitzgerald analyst Joseph France noted that it has been reported that UnitedHealth (UNH) is terminating its contract with Envision Healthcare (EVHC) because of alleged deficiencies in the latter's billing practices. He sees this as "particularly damaging" to Envision, both because of UnitedHealth's importance as a leading insurer and because it is central to Envision's effort to convert more of its business in-network. The analyst, who said client turnover could be a headwind for Envision in 2018-19, maintains his Neutral rating on the stock.
AEP American Electric
$64.12

-0.03 (-0.05%)

02/02/18
UBSW
02/02/18
INITIATION
Target $76
UBSW
Buy
American Electric initiated with a Buy at UBS
UBS analyst Daniel Ford started American Electric Power with a Buy rating and $76 price target.
02/20/18
GUGG
02/20/18
UPGRADE
GUGG
Neutral
American Electric upgraded to Neutral from Sell at Guggenheim
01/22/18
01/22/18
UPGRADE
Target $76

Outperform
American Electric upgraded to Outperform at Macquarie
As previously reported, Macquarie upgraded American Electric to Outperform from Neutral with a $76 price target, up from $73. Analyst Angie Storozynski sees further upside to earnings estimates given tax reform benefits and the Wind Catcher project, expected online in 2020. Storozynski raised estimates and said shares finally offer a good entry point.
01/22/18
MACQ
01/22/18
UPGRADE
MACQ
Outperform
American Electric upgraded to Outperform from Neutral at Macquarie
XEL Xcel Energy
$42.69

-0.03 (-0.07%)

02/02/18
UBSW
02/02/18
INITIATION
Target $47
UBSW
Neutral
Xcel Energy initiated with a Neutral at UBS
UBS analyst Daniel Ford started Xcel Energy with a Neutral rating and $47 price target.
02/13/18
MSCO
02/13/18
UPGRADE
MSCO
Overweight
Xcel Energy upgraded to Overweight from Equal Weight at Morgan Stanley
02/13/18
02/13/18
UPGRADE
Target $48

Overweight
Xcel Energy upgraded to Overweight with $48 target at Morgan Stanley
As previously reported, Morgan Stanley analyst Stephen Byrd upgraded Xcel Energy to Overweight from Equal Weight, citing the company's leverage to low-cost wind energy, which gives it above average earnings growth potential and lower regulatory hurdles. Byrd trimmed his price target on Xcel shares to $48 from $49.
03/27/18
MZHO
03/27/18
UPGRADE
Target $47
MZHO
Buy
Xcel Energy upgraded to Buy from Neutral at Mizuho
Mizuho analyst Paul Fremont upgraded Xcel Energy to Buy while reducing his price target for the shares to $47 from $49.50. The analyst raised his 2018 through 2021 estimates for the company to reflect higher capital spending at the utilities. He also sees an "additional upside opportunity" given the high likelihood of the company's Colorado Energy Project getting approved.
NEE NextEra Energy
$156.78

0.46 (0.29%)

12/06/17
GABE
12/06/17
NO CHANGE
GABE
Buy
NextEra Energy Partners named a Best Idea for 2018 at Gabelli
Gabelli analyst Tim Winter named NextEra Energy Partners (NEP) a Best Idea in the utility sector for 2018. The analyst sees significant drop-down opportunities from sponsor and general partner NextEra Energy (NEE). The analyst rates NextEra Energy Partners with a Buy and $46 PMV.
02/02/18
UBSW
02/02/18
INITIATION
Target $177
UBSW
Buy
NextEra Energy initiated with a Buy at UBS
UBS analyst Daniel Ford started NextEra Energy with a Buy rating and $177 price target.
12/07/17
FBCO
12/07/17
INITIATION
Target $173
FBCO
Outperform
NextEra Energy initiated with an Outperform at Credit Suisse
Credit Suisse analyst Michael Weinstein starts NextEra Energy with an Outperform rating and $173 price target. The analyst says the company's emphasis on a continent-wide non-regulated renewable development strategy is "extraordinary" among its integrated utility peers. He views NextEra as the "premier way to invest in a coming revolution for the electric generation industry."
12/14/17
HDLY
12/14/17
NO CHANGE
HDLY
Hilliard Lyons Top Ideas for Year-End 2017
Hilliard Lyons Research named its Top Ideas for Year-End 2017. They are: Pinnacle Financial (PNFP), Disney (DIS), J.M. Smucker (SJM), NextEra Energy (NEE), Zoetis (ZTS), Leggett & Platt (LEG), South Jersey Industries (SJI), Tanger Factory (SKT), Physicians Realty Trust (DOC), VMware (VMW), AT&T (T), and American Water (AWK).
EXC Exelon
$40.00

-0.14 (-0.35%)

03/29/18
03/29/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Exelon (EXC) upgraded to Neutral from Sell at Goldman Sachs by analyst Michael Lapides, with a $43 price target, as the analyst sees higher sum-of-parts value, potential upside to consensus estimates, and few near-term negative catalysts. 2. Harley-Davidson (HOG) upgraded to Neutral from Underperform at Longbow by analyst David MacGregor, citing valuation despite channel checks that indicate continued weakness in U.S. sales. MacGregor continues to be concerned about weak U.S. retail sales trends but views shares as fairly valued following his downgrade in January. 3. Jacobs Engineering (JEC) upgraded to Buy from Hold at Deutsche Bank by analyst Chad Dillard, who said the market is pricing in a near certain probability the CH2M merger integration will fail. He believes the concerns are overdone and thinks the risk of this merger is lower than other deals in the space. Jacobs management has a strong execution track record, Dillard contended. The analyst sees a path to 65% earnings growth and a doubling of free cash flow over the next three years. As such, he views the stock as "significantly undervalued." 4. Akamai (AKAM) upgraded to Equal Weight from Underweight at Morgan Stanley by analyst Keith Weiss. After a period of declining margins, he sees signs of stability, noting that following the involvement of activist Elliott Management the company has announced a 5% workforce reduction and new shareholder value initiatives. Also, the contribution from Akamai's top 6 Media customers looks to have stabilized after two years of steep declines and his customer survey indicating a more defensible core base, Weiss said. 5. Yandex (YNDX) upgraded to Buy from Neutral at Citi by analyst Brady Martin, who updated his model to reflect the company's better than expected fiscal 2017 financials as well as the taxi transaction with Uber that closed in February. Martin noted that Yandex continues to increase share on both desktop and mobile. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/28/18
GSCO
03/28/18
UPGRADE
GSCO
Neutral
Exelon upgraded to Neutral from Sell at Goldman Sachs
02/02/18
UBSW
02/02/18
INITIATION
Target $44
UBSW
Buy
Exelon initiated with a Buy at UBS
UBS analyst Daniel Ford started Exelon with a Buy rating and $44 price target.
03/28/18
GSCO
03/28/18
UPGRADE
GSCO
Neutral
Exelon upgraded to Neutral from Sell at Goldman Sachs
Goldman Sachs analyst Michael Lapides upgraded Exelon to Neutral from Sell with a $43 price target, as the analyst sees higher sum-of-parts value, potential upside to consensus estimates, and few near-term negative catalysts.
TWX Acquired by T
$95.36

-0.03 (-0.03%)

06/07/18
JEFF
06/07/18
DOWNGRADE
Target $35
JEFF
Hold
AT&T downgraded to Hold from Buy at Jefferies
Jefferies analyst John Janedis downgraded AT&T (T) to Hold and lowered his price target for the shares to $35 from $40 after assuming coverage of the name. Pressures in the company's entertainment segment will continue, as virtual multichannel video programming distributors gain share and video options pressure average revenue per user and margins, Janedis tells investors in a research note. He expects the Time Warner (TWX) acquisition to close, but believes there is risk of incremental programming investment at HBO/Turner to drive growth and that the advanced advertising opportunity may take longer to materialize.
04/17/18
PIVT
04/17/18
DOWNGRADE
Target $105
PIVT
Hold
Time Warner downgraded to Hold from Buy at Pivotal Research
Pivotal Research analyst Brian Wieser downgraded Time Warner (TWX) to Hold and lowered his price target for the shares to $105 from $108. The stock's value is driven by current trading levels of AT&T (T) under a presumption that the sale of the company goes through, Wieser tells investors in a research note.
06/01/18
RBCM
06/01/18
NO CHANGE
Target $360
RBCM
Outperform
RBC Capital backs Outperform rating on Netflix post U.S., international surveys
RBC Capital analyst Mark Mahaney reiterated an Outperform rating and $360 price target on Netflix (NFLX) shares following "positive" results from surveys in the U.S., France and German that found higher satisfaction trends, a rising willingness to pay for streaming content and high penetration levels. In the U.S., Mahaney noted that the survey found 55% of respondents watch Netflix, a significant lead over YouTube (GOOGL), Amazon (AMZN) and Hulu (DIS, CMCSA, TWX), adding that while Amazon is showing the fastest penetration growth among Streaming services, three years of data show that Prime customers are "more likely to also subscribe to Netflix." He views Netflix as one of the best derivatives off the strong growth in online video viewing and in Internet connect devices.
05/02/18
BRRR
05/02/18
NO CHANGE
Target $110
BRRR
Outperform
Odds in favor of Time Warner deal closing, says Barrington
Barrington analyst James Goss said he continues to expect the acquisition of Time Warner (TWX) by AT&T (T) to ultimately gain court approval and his Outperform rating in part reflects the significant gap from the AT&T takeout offer. He also sees relatively modest downside risk in the event of the deal being blocked, given the continued fundamental support based on existing Time Warner assets and operations, he tells investors. Goss maintains a $110 price target on Time Warner shares.
ABBV AbbVie
$100.41

1.115 (1.12%)

06/01/18
PIPR
06/01/18
NO CHANGE
PIPR
Overweight
Piper says Lilly should get some share for Olumiant with aggressive pricing
Piper Jaffray analyst Tyler Van Buren noted that the TNF step-through for Incyte (INCY) and Eli Lilly's (LLY) Olumiant potentially decreases the overall market opportunity, but he believes Olumiant will get some share of TNF failure patients given that Lilly announced it is pricing the drug "aggressively" at a potential 60% price discount to AbbVie's (ABBV) Humira. Van Buren estimates this price to be a potential 50% price discount to the other oral JAK approved for RA, Pfizer's (PFE) Xeljanz. The analyst keeps an Overweight rating on Incyte, citing the durable revenue base through the late 2020s that should come from Olumiant along with the "significant potential" he sees in its pipeline opportunities.
05/30/18
PIPR
05/30/18
INITIATION
Target $85
PIPR
Overweight
Gilead assumed with an Overweight at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren assumed coverage of Gilead Sciences (GILD) with an Overweight rating and $85 price target. The analyst, after speaking with management, has a "high level of conviction" that pricing for the hepatitis C virus franchise has finally stabilized. It is inconceivable that AbbVie (ABBV) will continue to be irrational on pricing, Van Buren tells investors in a research note.
06/01/18
PIPR
06/01/18
DOWNGRADE
Target $105
PIPR
Neutral
AbbVie downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Christopher Raymond downgraded AbbVie to Neutral and cut his price target for the shares to $105 from $138. The stock closed yesterday down 4%, or $4.07, to $98.94. The stock's risk/reward, while once compelling on the reward side, may be skewing increasingly toward risk, Raymond tells investors in a research note. The analyst thinks investors are underestimating the downside potential from Humira's looming loss of exclusivity in Europe in Q4. And while the U.S. model is very different, another headwind, co-pay accumulators, does not seem to be subsiding, Raymond adds. He thinks it is prudent to step to the sidelines with respect to AbbVie shares.
06/01/18
06/01/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Southwest (LUV) downgraded to In-Line from Outperform at Imperial Capital with analyst Michael Derchin saying he expects Southwest to face unit revenue pressures through fiscal 2019 from higher capacity growth in the "weaker" off-peak period as well as heightened competition in California and Denver. 2. AbbVie (ABBV) downgraded to Neutral from Overweight at Piper Jaffray with analyst Christopher Raymond saying the stock's risk/reward, while once compelling on the reward side, may be skewing increasingly toward risk. 3. Scotts Miracle-Gro (SMG) downgraded to Underweight from Neutral at JPMorgan with analyst Jeffrey Zekauskas saying the company faces challenges both in its core consumer business and in its hydroponics operation, which serves the cannabis market. 4. Owens Corning (OC) downgraded to Hold from Buy at Argus. 5. Perry Ellis (PERY) downgraded to Market Perform from Outperform at IFS Securities and to Neutral from Buy at Sidoti. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
PFE Pfizer
$36.67

0.18 (0.49%)

06/08/18
06/08/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Pfizer (PFE) and Eli Lilly (LLY) were initiated with an Overweight at Cantor Fitzgerald. 2. LivaNova (LIVN) initiated with a Buy at Stifel. 3. Occidental Petroleum (OXY) and Chevron (CVX) were initiated with a Buy at Mizuho while ConocoPhillips (COP) and Exxon Mobil (XOM) were initiated with a Neutral. 4. LeMaitre (LMAT) resumed with a Buy at Roth Capital. 5. Savara (SVRA) initiated with an Outperform, sees 300% upside, says Evercore ISI. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/08/18
CANT
06/08/18
INITIATION
Target $45
CANT
Overweight
Cantor sees 'respectable' earnings growth for Pfizer, starts at Overweight
Cantor Fitzgerald analyst Louise Chen last night initiated coverage of Pfizer with an Overweight rating and $45 price target. Despite loss of exclusivity headwinds to sales through the end of the decade, Pfizer can post "respectable" earnings growth driven by pipeline advancements and return of capital to shareholders, Chen tells investors in a research note. She sees multiple expansion and upward earnings revisions driving the stock higher.
06/07/18
CANT
06/07/18
INITIATION
Target $45
CANT
Overweight
Pfizer initiated with an Overweight at Cantor Fitzgerald
Cantor analyst Louise Chen initiated Pfizer with an Overweight and $45 price target.
MRK Merck
$62.57

0.6 (0.97%)

06/01/18
ROTH
06/01/18
NO CHANGE
Target $400
ROTH
Buy
Roth Capital ups Madrigal price target to $400, examines possible M&A scenarios
Roth Capital analyst Yasmeen Rahimi noted that Madrigal Pharmaceuticals' (MDGL) "impressive" NASH resolution results published yesterday resulted in the stock's value being pushed up to make it the highest among "purely NASH" companies. Among large pharma companies, Rahimi believes those with the strongest metabolic franchises, large R&D teams, and sales forces focused on endocrinologists, gastroenterologists, and hepatologists likely have eyes on NASH assets, listing Merck (MRK), AstraZeneca (AZN), Eli Lilly (LLY) and Novo Nordisk (NVO) as examples. The historical acquisition price for NASH assets ranges from $200M to $1.7B, but Rahimi argues that Madrigal "can set the highest NASH price tag yet," estimating a potential takeout valuation of $5.6B. Rahimi raised her price target on Madrigal shares to $400 from $210 and keeps a Buy rating on the stock.
05/17/18
WEDB
05/17/18
NO CHANGE
Target $53
WEDB
Outperform
Eiger BioPharmaceuticals price target raised to $53 from $36 at Wedbush
Wedbush analyst Liana Moussatos raised her price target for Eiger BioPharmaceuticals (EIGR) to $53 from $36 after the company expanded its licensing agreement with Merck (MRK) to include Hutchinson-Gilford Progeria Syndrome, or progeria, a fatal premature aging disease for which there are no approved drugs, after publication on April 24 in the Journal of the American Medical Association of Phase 2 results demonstrating a survival benefit -- after 2.2 years, only 1 of 27 lonafarnib-treated progeria syndrome patients died compared to 9 of 27 of untreated patients. In a research note to investors, Moussatos, who has an Outperform rating on shares, said that Eiger now has worldwide rights for progeria, HDV and all lonafarnib indications is a "game-changer" for the company.
05/18/18
PIPR
05/18/18
NO CHANGE
Target $28
PIPR
Overweight
Eiger BioPharmaceuticals price target raised to $28 from $17 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Eiger BioPharmaceuticals (EIGR) to $28 after the company expanded its lonafarnib licensing agreement with Merck (MRK) for rights in ultra-orphan indication Hutchinson-Gilford Progeria syndrome. The analyst now anticipates FDA approval of lonafarnib in HGPS in 2020. He reiterates an Overweight rating on Eiger shares.
05/24/18
MZHO
05/24/18
NO CHANGE
Target $103
MZHO
Buy
Nektar is Bristol-Myers' best chance in immuno-oncology, says Mizuho
Nektar Therapeutics' (NKTR) NKTR-214 asset is the best shot Bristol-Myers Squibb (BMY) has to retain its footing in the competitive immuno-oncology space, Mizuho analyst Difei Yang tells investors in a research note. The analyst says that recent data in non-small cell lung cancer presented by Merck (MRK) on Keytruda saw the company jump ahead of Bristol's Opdivo in this key indication. Upcoming data of the Opdivo/NKTR-214 combo at ASCO on June 2 will be key on 100 patients across multiple indications, Yang contends. She believes Bristol stands at risk of losing significant market share in the growing immuno-oncology space. Ahead of the data, the analyst reiterates a Buy rating on Nektar with a $103 price target.
BMY Bristol-Myers
$53.16

0.56 (1.06%)

05/16/18
PIPR
05/16/18
NO CHANGE
Target $125
PIPR
Overweight
Nektar 214+nivo response for melanoma not conclusive, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren keeps his Overweight rating and $125 price target on Nektar (NKTR) after the release of PIVOT ASCO abstract of NKTR 214+nivo (BMY). The analyst says that while the 1L melanoma response rate may be "slightly lower than some had hoped for", the 1L RCC response rate were "nicely above" what has been seen with ipi+nivo treatment. Van Buren adds that while small in numbers, "3/4 responses in 1L bladder and 1/3 responses in triple negative breast cancer are encouraging." The analyst believes that the stock may be down in the morning, but investors should not come to "rash conclusions", as the ASCO presentation with more patients and detail is likely to be positive.
05/21/18
UBSW
05/21/18
DOWNGRADE
Target $57
UBSW
Neutral
Bristol-Myers downgraded to Neutral from Buy at UBS
UBS analyst Marc Goodman downgraded Bristol-Myers to Neutral from Buy. Goodman lowered his price target to $57 from $67 on Bristol-Myers shares.
05/21/18
05/21/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Bristol-Myers (BMY) downgraded to Neutral from Buy at UBS. 2. Campbell Soup (CPB) downgraded to Underperform from Neutral at BofA/Merrill with analyst Bryan Spillane saying he expects 2019 to be a transition year and for operating profits and earnings to decline modestly. 3. American Eagle (AEO) downgraded to Hold from Buy at SunTrust with analyst Pamela Quintilliano saying the fundamentals are not catching up to the continued advance in the stock price. 4. Andeavor Logistics (ANDX) downgraded to Neutral from Overweight at JPMorgan with analyst Jeremy Tonet citing the new drop outlook following the parent merger announcement as well as lower than expected Q1 estimates. 5. Williams Partners (WPZ) downgraded to Hold from Buy at Stifel and to Outperform from Strong Buy at Raymond James. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
JNJ Johnson & Johnson
$124.04

0.76 (0.62%)

04/18/18
WELS
04/18/18
NO CHANGE
Target $150
WELS
Outperform
Johnson & Johnson price target lowered to $150 from $160 at Wells Fargo
Wells Fargo analyst Lawrence Biegelsen lowered his price target for Johnson & Johnson to $150 from $160 following quarterly results. The analyst reiterates an Outperform rating on the shares.
05/17/18
LEER
05/17/18
NO CHANGE
Target $160
LEER
Outperform
Leerink confidence in Johnson & Johnson increased by analyst day meeting
Leerink analyst Danielle Antalffy said she came away from Johnson & Johnson's Medical Devices & Consumer analyst day "increasingly confident" that these segments will be able to return to and outpace overall market growth over 2017-22. The analyst, who still sees J&J ultimately returning to and sustaining a "solid mid-single-digit" revenue growth trajectory with upside potential, reiterates her Outperform rating and $160 price target on Johnson & Johnson shares.
06/06/18
JEFF
06/06/18
NO CHANGE
Target $49
JEFF
Buy
Pacira sales inflection may 'finally be underway,' says Jefferies
After hosting an investor dinner with Pacira Pharmaceuticals (PCRX) CEO Dave Stack, Jefferies analyst David Steinberg believes a "meaningful sales inflection for Exparel may finally be underway." Management is increasingly confident that an Exparel sales inflection, driven by the Johnson & Johnson (JNJ) partnership and expanded nerve block indication, is underway, Steinberg tells investors in a research note. Further, he believes a "potentially significant" Exparel rest-of-work partnership is likely to be announced prior to the end of 2018. The analyst keeps a Buy rating on Pacira Pharmaceuticals with a $49 price target.
06/05/18
CANT
06/05/18
NO CHANGE
Target $510
CANT
Overweight
Medtronic robot delay 'clear positive' for Intuitive Surgical, says Cantor
Medtronic (MDT) today at its analyst meeting said it expects commercial launch of its surgical robot in fiscal 2020, which is roughly a year delay compared to the company's prior expectations, Cantor Fitzgerald analyst Craig Bijou tells investors in a research note partially titled "ISRG's Headstart Gets Bigger." The analyst views the revised timing of the commercial launch of Medtronic's robot as a "clear positive" for Intuitive Surgical (ISRG). With the commercial launches of the Medtronic and Johnson & Johnson (JNJ) robots at least 18 months away, Intuitive should continue to grow its global installed base, further advancing its global surgical robotics leadership position, Bijou writes. He reiterates his Overweight rating on the shares with a $510 price target. The stock in afternoon trading is up $8.46 to $486.39.
LLY Eli Lilly
$86.13

0.27 (0.31%)

06/07/18
CANT
06/07/18
INITIATION
Target $100
CANT
Overweight
Eli Lilly initiated with an Overweight at Cantor Fitzgerald
Cantor analyst Louise Chen initiated Eli Lilly with an Overweight and $100 price target.
06/08/18
CANT
06/08/18
INITIATION
Target $100
CANT
Overweight
Cantor calls Eli Lilly pipeline underappreciated, initiates with Overweight
Cantor Fitzgerald analyst Louise Chen last night initiated coverage of Eli Lilly with an Overweight rating and $100 price target. The growth prospects for Lilly's key drugs, Trulicity, Jardiance, Taltz and Verzenio, as well as its pipeline assets, especially in pain, are underappreciated, Chen tells investors in a research note. She thinks the company's sales growth, margin expansion, and pipeline advancements will more than offset competition for older products. As such, Chen thinks multiple expansion and upward earnings revisions will drive the stock higher.
LUV Southwest
$50.48

-0.16 (-0.32%)

06/01/18
IMPC
06/01/18
DOWNGRADE
Target $54
IMPC
In-Line
Southwest downgraded to In-Line from Outperform at Imperial Capital
Imperial Capital analyst Michael Derchin downgraded Southwest Airlines to In-Line and cut his price target for the shares to $54 from $68. The analyst expects Southwest to face unit revenue pressures through fiscal 2019 from higher capacity growth in the "weaker" off-peak period as well as heightened competition in California and Denver. He estimates the company's unit revenues will be flat in fiscal 2018 and increase 1% in fiscal 2019, versus roughly 2.5% and 2% for the industry, respectively.
05/25/18
TIGR
05/25/18
INITIATION
TIGR
Buy
Southwest initiated with a Buy at Tigress Financial
Tigress Financial analyst Ivan Feinseth initiated Southwest with a Buy rating, citing his view that strong travel industry trends and the company's industry-leading position can keep driving increased revenue and profitability growth. He sees the recent pullback from the stock's all-time high near $67 per share as a good entry point, he tells investors.
05/07/18
IMPC
05/07/18
NO CHANGE
Target $74
IMPC
Outperform
Hawaiian Holdings competitive concerns overblown, says Imperial Capital
Imperial Capital analyst Michael Derchin believes competitive concerns around Hawaiian Holdings (HA) are overblown after Southwest (LUV) indicated its intention to serve Hawaii from Oakland, San Diego, San Jose and Sacramento. Importantly, Southwest did not announce service from Los Angeles or San Francisco, Hawaiian's two biggest cities on the West Coast, Derchin tells investors in a research note. The analyst believes Hawaiian is likely to retain its leading market share inter-island, particularly among local travelers. He expects the company to grow earnings through 2020 given its "strong" brand loyalty, "superior" product and partnership with Japan Air Lines. Derchin lowered his price target for Hawaiian Holdings to $74 from $82 and keeps an Outperform rating on the shares.
BMWYY BMW
$0.00

(0.00%)

01/02/18
EVER
01/02/18
DOWNGRADE
EVER
In Line
BMW downgraded to In Line from Outperform at Evercore ISI
01/05/18
JPMS
01/05/18
DOWNGRADE
JPMS
Underweight
BMW downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Jose Asumendi downgraded BMW to Underweight.
04/05/18
BERN
04/05/18
NO CHANGE
BERN
BMW, Tesla among 'biggest losers' following Chinese tariffs, says Bernstein
Bernstein analyst Robin Zhu notes that China's Ministry of Commerce announced 25% incremental tariffs on U.S. imports of 106 types of goods, including essentially all automobiles, soy beans, chemicals, aircraft, and other goods. If enforced, this would mean cars imported from the U.S. would face 50% import tariffs, up from the usual 25%. The analyst believes the biggest losers would be BMW (BMWYY), Mercedes (DDAIF), Tesla (TSLA). BMW and Mercedes import the largest volumes of cars from the U.S. into China, followed by is Tesla with14k units of projected imports, he points out.
05/31/18
MSCO
05/31/18
NO CHANGE
Target $28
MSCO
Overweight
Fiat Chrysler ending Fiat sales in U.S. would be 'sensible,' says Morgan Stanley
Morgan Stanley analyst Adam Jonas said he believes that if Bloomberg is correct and Fiat Chrysler (FCAU) does plan to stop selling Fiat branded cars in North America and China it would be a "sensible recognition" of how to allocate capital over the next five years. BMW (BMWYY), including MINI, sells 21 times more cars in the U.S. than Fiat does, noted Jonas, who said Bloomberg's report appears consistent with his high-level expectation that FCA will send the message that it is cutting investment or possibly exiting areas that don't add shareholder value and "doubling down"' on brands and businesses, like Jeep, that have untapped global potential. Jonas maintains an Overweight rating on Fiat Chrysler shares with a $28 price target.
VLKAY Symbol is now VWAGY
$0.00

(0.00%)

05/31/18
JEFF
05/31/18
NO CHANGE
JEFF
Buy
Jefferies lists buys on 'wildly overdone' electric truck concerns
The ramp of electric trucks amp may be slower than in passenger cars, and incumbent truck makers are likely to remain key players, Jefferies analyst Stephen Volkmann tells investors in a research note. To a much greater extent than in passenger vehicles, commercial vehicle sales rely on uptime and return on investment, and are driven by brand relationship and dealer support, Volkmann adds. He views the "terminal multiple" concerns for established truck players as "wildly overdone" and recommends buying shares of Paccar (PCAR), Navistar (NAV), Volkswagen (VLKAY) and Volvo (VOLVY).
04/25/18
JEFF
04/25/18
NO CHANGE
Target $53
JEFF
Buy
VW acquisition scenario supports $53 Navistar target, says Jefferies
Recent news flow regarding a separation of Volkswagen's (VLKAY) Truck and Bus business and the potential for full ownership of Navistar (NAV) has driven Navistar shares up 13% relative to the S&P 500 over the past month, Jefferies analyst Stephen Volkmann tells investors in a research note. After examining potential synergies and valuation scenarios for a tie-up, the analyst has increased confidence in his high-on-the-Street $53 price target for Navistar shares.
04/25/18
PIPR
04/25/18
NO CHANGE
Target $44
PIPR
Overweight
Navistar takeout bid below $44 would be too low, says Piper Jaffray
After traveling with management, Piper Jaffray analyst Alexander Potter reiterates an Overweight rating on Navistar International (NAV) with a $44 price target. Any potential acquirer would use discounted cash flow to capture Navistar's potential for multi-year margin and market share growth, Potter tells investors in a research note. Even before last week's "media frenzy re-ignited take-out speculation," many investors had already believed Navistar would ultimately be acquired by alliance partner Volkswagen (VLKAY), the analyst contends. Potter adds that any Volkswagen bid below $44 per share would be too low. The analyst thinks Navistar shares "are too cheap."
04/25/18
JEFF
04/25/18
UPGRADE
JEFF
Buy
Volkswagen upgraded to Buy from Hold at Jefferies
Jefferies analyst Philippe Houchois upgraded Volkswagen to Buy and raised his price target for the shares to EUR 220 from EUR 180. The analyst likes the recent management changes but says what matters most is the "generational change at Porsche SE," which he views as VW's "most promising agent of change." The analyst is "convinced" that VW-Porsche have what it takes to be the next FCA-Exor.
AABA Altaba
$80.58

0.88 (1.10%)

06/07/18
FBCO
06/07/18
NO CHANGE
Target $88
FBCO
Altaba price target raised to $88 from $76 at Credit Suisse
Credit Suisse analyst Stephen Ju raised his price target for Altaba (AABA) to $88 from $76, citing the 195M share tender offer, and Alibaba (BABA) and Yahoo Japan (YAHOY) share prices.
05/18/18
MKMP
05/18/18
NO CHANGE
Target $124
MKMP
Buy
Altaba price target raised to $124 from $112 at MKM Partners
MKM Partners analyst Rob Sanderson raised his price target on Altaba (AABA) to $124 to reflect the price target change on Alibaba (BABA). The analyst anticipates "aggressive" share repurchases by the company to continue based on the management's view that Altaba discount to net asset value will normalize "below the effective tax rate", and that the tax rate will land in the high teens and below the 21% federal target rate. Sanderson further believes that the resulting arbitrage opportunity should remain "highly favorable".
03/29/18
RHCO
03/29/18
NO CHANGE
Target $225
RHCO
Buy
Facebook sell-off is 'overdone', says SunTrust
SunTrust analyst Youssef Squali writes that the 17% decline in the stock price of Facebook (FB) since the emergence of the Cambridge Analytica scandal last week is overdone, keeping his Buy rating and $225 price target. Squali notes that the digital advertisers he spoke with are not leaving the platform because of Facebook's marketing effectiveness and also sees few signs of "users fleeing Facebook en masse". The analyst further points to "compelling valuation" on the shares, the likelihood of limited regulatory actions, and the history of the spillover from other data breach instances impacting companies like Yahoo (AABA) and Equifax (EFX) eventually passing.
02/28/18
FBCO
02/28/18
NO CHANGE
Target $86
FBCO
Neutral
Altaba price target raised to $86 from $81 at Credit Suisse
Credit Suisse analyst Stephen Ju raised his price target for Altaba (AABA) to $86 from $81, citing Alibaba (BABA) and Yahoo Japan (YAHOY) share prices, updated cash balance and share count per latest annual filing disclosure, and updated cost basis for Alibaba and Yahoo Japan ownership stakes. The analyst reiterates a Neutral rating on Altaba shares.

TODAY'S FREE FLY STORIES

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
06/19/19
06/19
13:17
06/19/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
06/19/19
06/19
13:16
06/19/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BK

BNY Mellon

$42.95

-0.27 (-0.62%)

13:15
06/19/19
06/19
13:15
06/19/19
13:15
Options
BNY Mellon put volume heavy and directionally bearish »

Bearish flow noted in BNY…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 06

    Aug

RIO

Rio Tinto

$59.44

-2.745 (-4.41%)

13:06
06/19/19
06/19
13:06
06/19/19
13:06
Hot Stocks
Rio Tinto drops over 4% after reporting operational challenges »

Earlier today, Rio Tinto…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AWK

American Water

$116.95

0.28 (0.24%)

13:03
06/19/19
06/19
13:03
06/19/19
13:03
Hot Stocks
California American Water desalination project wins $10M state grant »

The California Department…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAT

Mattel

$11.62

-0.435 (-3.61%)

13:02
06/19/19
06/19
13:02
06/19/19
13:02
Hot Stocks
MGA calls off Mattel merger talks, says 'too much mess to clean up' »

MGA Entertainment CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEVA

Teva

$8.30

-0.045 (-0.54%)

13:01
06/19/19
06/19
13:01
06/19/19
13:01
Hot Stocks
Teva announces U.S. launch of generic version of Tracleer »

Teva Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Z

Zillow

$45.36

-1.1 (-2.37%)

13:00
06/19/19
06/19
13:00
06/19/19
13:00
Options
Zillow put buyer opens new short-term position »

Zillow put buyer opens…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAT

Mattel

$11.62

-0.43 (-3.57%)

12:59
06/19/19
06/19
12:59
06/19/19
12:59
Hot Stocks
Breaking Hot Stocks news story on Mattel »

MGA Entertainment CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHS

Chico's

$3.24

0.14 (4.52%)

12:56
06/19/19
06/19
12:56
06/19/19
12:56
Hot Stocks
Sycamore Partners lowers takeover offer to Chico's to $3.00 per share »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBAY

CymaBay

$7.00

-0.09 (-1.27%)

12:55
06/19/19
06/19
12:55
06/19/19
12:55
Options
CymaBay put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAT

Mattel

$11.58

-0.47 (-3.90%)

12:55
06/19/19
06/19
12:55
06/19/19
12:55
Hot Stocks
Breaking Hot Stocks news story on Mattel »

MGA Entertainment says no…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KKR

KKR

$23.93

0.57 (2.44%)

12:50
06/19/19
06/19
12:50
06/19/19
12:50
Periodicals
KKR close to selling partial stake in $2B helicopter firm, Bloomberg says »

According to Elffie Chew…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHS

Chico's

$3.24

0.14 (4.52%)

12:49
06/19/19
06/19
12:49
06/19/19
12:49
Hot Stocks
Chico's erases gains after Bloomberg says Sycamore again lowered bid »

Chico's in midday…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHS

Chico's

$3.25

0.145 (4.68%)

12:48
06/19/19
06/19
12:48
06/19/19
12:48
Periodicals
Sycamore Partners lowers bid for Chico's to $3 per share, Bloomberg reports »

Sycamore Partners has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIS

General Mills

$52.59

0.15 (0.29%)

12:45
06/19/19
06/19
12:45
06/19/19
12:45
Options
General Mills call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 09

    Jul

  • 10

    Jul

  • 11

    Jul

BIDU

Baidu

$117.13

0.26 (0.22%)

12:41
06/19/19
06/19
12:41
06/19/19
12:41
Periodicals
Baidu says Apollo Lite framework achieves level 4 autonomy, VB reports »

According to VB's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jun

KR

Kroger

$23.62

-0.32 (-1.34%)

, DRI

Darden

$116.14

-1.8 (-1.53%)

12:35
06/19/19
06/19
12:35
06/19/19
12:35
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

KR

Kroger

$23.62

-0.32 (-1.34%)

DRI

Darden

$116.14

-1.8 (-1.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 20

    Jun

  • 25

    Jun

  • 27

    Jun

MDR

McDermott

$7.69

0.065 (0.85%)

12:35
06/19/19
06/19
12:35
06/19/19
12:35
Options
McDermott put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:35
06/19/19
06/19
12:35
06/19/19
12:35
General news
FOMC forecast preview: »

FOMC forecast preview:…

ORCL

Oracle

$52.80

-0.08 (-0.15%)

12:35
06/19/19
06/19
12:35
06/19/19
12:35
Earnings
Notable companies reporting after market close »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

GME

GameStop

$5.65

-0.08 (-1.40%)

, ATVI

Activision Blizzard

$45.02

-0.76 (-1.66%)

12:33
06/19/19
06/19
12:33
06/19/19
12:33
Hot Stocks
GameStop says new 'Call of Duty' most pre-ordered video game following E3 »

GameStop (GME) said that…

GME

GameStop

$5.65

-0.08 (-1.40%)

ATVI

Activision Blizzard

$45.02

-0.76 (-1.66%)

NTDOY

Nintendo

$0.00

(0.00%)

TTWO

Take-Two

$109.38

-1.61 (-1.45%)

EA

Electronic Arts

$92.38

0.35 (0.38%)

MSFT

Microsoft

$134.54

-0.66 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 20

    Jun

  • 23

    Jun

  • 25

    Jun

  • 09

    Jul

  • 10

    Jul

  • 06

    Aug

  • 13

    Nov

INO

Inovio

$2.61

-0.02 (-0.76%)

12:25
06/19/19
06/19
12:25
06/19/19
12:25
Conference/Events
Inovio management to meet with Piper Jaffray »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

SHOP

Shopify

$316.25

11.94 (3.92%)

12:25
06/19/19
06/19
12:25
06/19/19
12:25
Conference/Events
Shopify to host investor day »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 05

    Sep

EVBG

Everbridge

$89.89

1.36 (1.54%)

12:25
06/19/19
06/19
12:25
06/19/19
12:25
Conference/Events
Everbridge to host analyst & investor meeting »

Analyst & Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.